

Jonathan T Lei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2495112/publications.pdf>

Version: 2024-02-01

46
papers

2,728
citations

567281

15
h-index

713466

21
g-index

48
all docs

48
docs citations

48
times ranked

5618
citing authors

#	ARTICLE	IF	CITATIONS
1	Proteogenomics connects somatic mutations to signalling in breast cancer. <i>Nature</i> , 2016, 534, 55-62.	27.8	1,384
2	Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. <i>Cell</i> , 2020, 183, 1436-1456.e31.	28.9	273
3	Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 361-379.e16.	16.8	189
4	Pulmonary alveolar proteinosis caused by deletion of the GM-CSFR β gene in the X chromosome pseudoautosomal region 1. <i>Journal of Experimental Medicine</i> , 2008, 205, 2711-2716.	8.5	171
5	A proteogenomic portrait of lung squamous cell carcinoma. <i>Cell</i> , 2021, 184, 4348-4371.e40.	28.9	170
6	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. <i>Cell Reports</i> , 2018, 24, 1434-1444.e7.	6.4	73
7	ESR1 alterations and metastasis in estrogen receptor positive breast cancer. <i>Journal of Cancer Metastasis and Treatment</i> , 2019, 2019, .	0.8	62
8	Endocrine therapy resistance: new insights. <i>Breast</i> , 2019, 48, S26-S30.	2.2	60
9	Neurofibromin Is an Estrogen Receptor β Transcriptional Co-repressor in Breast Cancer. <i>Cancer Cell</i> , 2020, 37, 387-402.e7.	16.8	59
10	Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. <i>Cancer Discovery</i> , 2017, 7, 1168-1183.	9.4	58
11	Proteomic profiling identifies key coactivators utilized by mutant ER β proteins as potential new therapeutic targets. <i>Oncogene</i> , 2018, 37, 4581-4598.	5.9	51
12	DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11978-E11987.	7.1	40
13	JAK kinases control IL-5 receptor ubiquitination, degradation, and internalization. <i>Journal of Leukocyte Biology</i> , 2007, 81, 1137-1148.	3.3	37
14	Separate endocytic pathways regulate IL-5 receptor internalization and signaling. <i>Journal of Leukocyte Biology</i> , 2008, 84, 499-509.	3.3	29
15	Three Lysine Residues in the Common β Chain of the Interleukin-5 Receptor Are Required for Janus Kinase (JAK)-dependent Receptor Ubiquitination, Endocytosis, and Signaling. <i>Journal of Biological Chemistry</i> , 2011, 286, 40091-40103.	3.4	16
16	ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1526005.	0.7	16
17	Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. <i>Cancer Research</i> , 2021, 81, 6259-6272.	0.9	10
18	Proteogenomics drives therapeutic hypothesis generation for precision oncology. <i>British Journal of Cancer</i> , 2021, 125, 1-3.	6.4	8

#	ARTICLE	IF	CITATIONS
19	Copy number alterations associated with clinical features in an underrepresented population with breast cancer. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e00750.	1.2	7
20	Mammary Ductal Environment Is Necessary for Faithful Maintenance of Estrogen Signaling in ER + Breast Cancer. <i>Cancer Cell</i> , 2016, 29, 249-250.	16.8	6
21	LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 49.	5.2	4
22	Abstract P6-04-04: Functional characterization ofESR1fusions in breast cancer. , 2020, , .		1
23	Regulatory signals mediating down-regulation of the common beta chain of the IL-5, IL-3, and GM-CSF receptors*1. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, S334.	2.9	0
24	Endocytic pathways regulating down-regulation of the Interleukin-5 receptor. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, S121.	2.9	0
25	Interleukin-5 Receptor Endocytosis is Regulated by Two Distinct Pathways. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, S234.	2.9	0
26	Regulation of IL-5 Receptor Endosomal Trafficking by Ubiquitin. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 791.	2.9	0
27	IL-5 Receptor Trafficking Is Regulated By Tyrosine Phosphorylation. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 725-726.	2.9	0
28	Î²c Ubiquitination is a Molecular Signature for IL-5 Receptor Endocytosis and Signaling. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, AB117.	2.9	0
29	The Common Beta Chain Phosphorylation Axis Controls IL-5 Receptor Sub-cellular Distribution. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, AB165-AB165.	2.9	0
30	Abstract PD8-02: Kinome profiling of ER+ breast cancer PDXs identifies PKMYT1 as a marker of hormone independent growth and poor outcome. , 2021, , .		0
31	Abstract PS17-03: Recurrent activeESR1fusions render a diagnostic transcriptional signature in metastatic breast cancer. , 2021, , .		0
32	Abstract 742: The integration of a structure-function rule and a transcriptional signature to assignESR1fusion activity in metastatic breast cancer. , 2021, , .		0
33	Abstract 2490: Optimizing treatment strategy for NF1-depleted estrogen receptor positive breast cancer. , 2021, , .		0
34	Abstract 2992: Proteogenomic characterization of triple-negative breast cancer patient-derived xenografts reveals molecular correlates of differential chemotherapy response and potential therapeutic targets to overcome resistance. , 2021, , .		0
35	Abstract 18: Molecular dissection of chemotherapy response in triple negative breast cancer (TNBC) using microscaled proteogenomics. , 2021, , .		0
36	Abstract P1-08-07: Assessing the impact of loss of NF1 protein on endocrine therapy resistance. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
37	Abstract 1033: Estrogen receptor gene fusions drive endocrine therapy resistance in estrogen receptor positive breast cancer. , 2017, , .		0
38	Abstract 5240: Functional and therapeutic significance of ESR1 gene fusions in breast cancer. , 2018, , .		0
39	Abstract 1814: NF1 as an estrogen receptor- β co-repressor in breast cancer. , 2018, , .		0
40	Abstract 3479: Functional significance of ESR1 fusions with diverse gene partners in endocrine therapy resistant breast cancer. , 2019, , .		0
41	Abstract 850: Evaluating preclinical efficacy of anti-HER2 drug combinations using ER+/HER2 mutant models. , 2019, , .		0
42	Abstract 5118: Proteogenomics characterization of HPV-negative head and neck squamous cell carcinomas. , 2020, , .		0
43	Abstract 5467: Outlier analysis to identify determinants of therapeutic resistance in breast cancer. , 2020, , .		0
44	Abstract 4385: Proteogenomics-driven synthetic lethality discovery to predict targetable protein dependencies induced by somatic deletions. , 2020, , .		0
45	Abstract P5-07-01: Proteogenomic analysis of differential chemotherapy responses in patient-derived xenografts of triple-negative breast cancer. Cancer Research, 2022, 82, P5-07-01-P5-07-01.	0.9	0
46	Targeting kinome reprogramming in ESR1 fusion-driven metastatic breast cancer.. Journal of Clinical Oncology, 2022, 40, 1085-1085.	1.6	0